UNSPSC 51371503: Desmethylmoramide

This classification denotes an opioid receptor agonist with the molecular formula C24H30N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9B1Z1V29C3, chemically known as 1-(4-morpholino-2,2-diphenylbutyryl)pyrrolidine but generally known as desmethylmoramide, which bears US NIH Compound Identifier 206005. European Medicines Agency schedules Desmethylmoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07000MIG. The term DESMETHYLMORAMIDE is an International Non-Proprietary Name.

UNSPSC 51371503 Desmethylmoramide, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three posted opportunities—Seminole County's procurement of naloxone and drug deactivation systems, Texas Health and Human Services Commission's request for information on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and over-the-counter products—focus on naloxone distribution, pharmacy benefit program restructuring, and broad-based pharmaceutical supply, none of which involve desmethylmoramide as a discrete procurement target. The coding mismatch suggests that state and local procurement offices are either tagging these opportunities incorrectly or using the code as a broader family catch-all for specialty pharmaceutical activity rather than for this specific controlled substance.

The issuing bodies span state health departments, county health systems, and cooperative purchasing alliances: Seminole County, Florida (county health procurement); Texas Health and Human Services Commission (state agency); and Minnesota Department of Administration / MMCAP (state-level cooperative vehicle serving multiple jurisdictions including Oregon). Geographic activity appears concentrated in the Southeast (Florida) and upper Midwest (Minnesota, participating states) with exploratory activity in Texas. The Seminole County IFB (Solicitation IFB60459723LAS) closing July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas RFI (HHS0017013, April 3, 2026) gathered market intelligence on direct pharmaceutical contracting before formal procurement; and the MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals across cooperating jurisdictions. The code shows little relevant recent activity and does not reflect the actual pharmaceutical and overdose-response products state and local governments are currently buying.